Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 6868-year-old man is evaluated in the outpatient cardiology clinic for ongoing symptoms of heart failure. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of 25%25\%. He currently reports dyspnea when walking up a single flight of stairs (New York Heart Association class III). His daily medications include sacubitril-valsartan, carvedilol, and empagliflozin. He is adherent to a low-sodium diet. Vital signs show a blood pressure of 112/74112/74 mmHg and a pulse of 6868/min. Physical examination reveals clear lungs and trace bilateral lower extremity edema. Recent laboratory studies show:

Laboratory TestResult
Serum sodium138138 mEq/L
Serum potassium4.34.3 mEq/L
Blood urea nitrogen1818 mg/dL
Serum creatinine1.11.1 mg/dL

To further reduce mortality and hospitalizations, the physician decides to initiate spironolactone at a dose of 12.512.5 mg daily.

Which of the following represents the most appropriate monitoring or management strategy for this patient's new therapeutic regimen?

  1. Measure serum potassium and creatinine levels in 1 to 2 weeks.Answer
  2. B
    Cancel the spironolactone prescription, as it is contraindicated with his current medication regimen.
  3. C
    Discontinue empagliflozin prior to initiation to prevent severe drug-induced nephrotoxicity.
  4. D
    Order a right heart catheterization to assess central hemodynamics before adding new agents.
  5. E
    Obtain a 24-hour urine protein collection to establish a renal baseline prior to therapy.

Answer

Measure serum potassium and creatinine levels in 1 to 2 weeks.
The initiation of a mineralocorticoid receptor antagonist (MRA) such as spironolactone is a Class I recommendation for patients with symptomatic heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality. Because MRAs inhibit the action of aldosterone in the distal nephron, they decrease renal potassium excretion, posing a significant risk of hyperkalemia. They can also cause an acute decline in the estimated glomerular filtration rate (eGFR). Current cardiology guidelines mandate checking serum potassium and renal function (creatinine) within 1 to 2 weeks after initiating or titrating an MRA, and periodically thereafter.

Step-by-Step Solution

1
Analyze the patient's diagnosis and new prescription.
The patient has HFrEF and is being started on spironolactone, a mineralocorticoid receptor antagonist (MRA).
Identifying the drug class is essential for recalling specific monitoring guidelines and side effect profiles.
2
Determine the primary adverse effects associated with MRA initiation.
MRAs block aldosterone, leading to decreased renal potassium excretion and potential alterations in renal hemodynamics.
Understanding the mechanism of action explains the risk of hyperkalemia and acute kidney injury.
3
Apply guideline-directed monitoring parameters.
Guidelines mandate checking a basic metabolic panel (specifically potassium and creatinine) within 1 to 2 weeks after initiating or titrating an MRA.
Early detection of hyperkalemia prevents life-threatening arrhythmias, particularly in patients on concurrent renin-angiotensin-aldosterone system inhibitors.

Key Concept

Following the initiation or dose escalation of a mineralocorticoid receptor antagonist (such as spironolactone), serum potassium and renal function must be reassessed within 1 to 2 weeks due to the high risk of potentially fatal hyperkalemia and acute kidney injury.
Estimated Time:1m 15s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic